Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Oct 2016
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PROTECT
- 18 Oct 2016 Planned number of patients changed from 88 to 4.
- 18 Oct 2016 Planned End Date changed from 1 Nov 2017 to 1 Jul 2017.
- 18 Oct 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Jul 2017.